India US FDA India Office Director Sarah McMullen discusses the importance of maintaining India’s role as a global supplier of low-cost generics while also navigating the complexities of innovating and producing more complex pharmaceutical products. She notes that increased product complexity will inevitably lead to more regulatory challenges, emphasizing the need…
China In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due diligence. Servier’s Asia BD Head Cynthia Xin Wang explains how this shift reflects changing market dynamics and the growing importance…
Africa Nigeria has become the first country to roll out a new meningitis vaccine. The product, a shot able to protect against the five causes of meningococcal meningitis, was developed by the Serum Institute of India (SIIPL) and health equity non-profit PATH. With more meningitis vaccine-based projects in the pipeline, stakeholders…
China Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma landscape. Executive President Prof. Song Ruilin outlines the advances and some of the challenges and opportunities facing China’s biotech and…
Africa Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status. While acknowledging the importance of international actors in making this happen, Hwenda argues that – if the African Medicines Agency…
Saudi Arabia Baxter Saudia Arabia GM Faisal BinDail shares some insights into the renal care specialist’s local manufacturing hub, the sole manufacturing site for peritoneal dialysis products in the Middle East, and the company’s plans to expand its reach in Saudi Arabia and the broader region. We aim to provide our…
Saudi Arabia Basel Al-Qahtani, General Manager of Boston Scientific Saudi Arabia, discusses how Boston Scientific has expanded its operations to establish a fully fledged regional headquarters in the kingdom. He outlines the company’s commitment to Saudi Arabia’s Vision 2030 agenda through public-private partnerships and potentially through accountable care organizations, and underlines the…
Saudi Arabia Since joining Moderna as its first ex-US commercial employee in Spring 2020, Dan Staner has played a leading role in developing what is now one of the world’s top 20 biggest pharma companies. Speaking exclusively to PharmaBoardroom, Staner describes how Moderna has been able to fashion a new, optimised company…
Saudi Arabia Newly-appointed SPIMACO CEO Jérôme Cabannes outlines the ongoing transformation and growth of SPIMACO, focusing on leveraging existing assets while expanding through partnerships, new technologies, and market diversification. He highlights the company’s shift towards more complex products, such as biosimilars, and how its international acquisitions align with Saudi Arabia’s Vision 2030…
Saudi Arabia SPIMACO is well-known within the Middle East and North Africa, but less so internationally. Chairman Ahmed Aljedai explains how the company is changing that by actively expanding its international presence, including via acquisitions in Europe. He also traces SPIMACO’s journey towards becoming a full-spectrum pharma company covering the entire value…
Italy A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between Venatorx Pharmaceuticals and Menarini, and the country’s drop in healthcare spending. Stevanato Group Announces Public Offering of Ordinary Shares…
China Reporting from Chinese language media outlet Yaozh, based on recently issued annual financial reporting, shows the leading R&D spenders among the (predominantly mainland Chinese) biotech companies listed on the Hong Kong Stock Exchange (HKEX). Local heavyweight Beigene invested almost three times as much on R&D last year as its nearest…
See our Cookie Privacy Policy Here